Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Autoimmune Disorders

  Free Subscription


2 Ann Neurol
6 Brain
1 Diabet Med
7 Diabetes
3 Int J Clin Pract
3 Intern Med
2 J Clin Endocrinol Metab
3 J Immunol
1 J Nephrol
3 J Neuroimmunol
2 J Neurol
2 Kidney Int
24 Mult Scler
1 N Engl J Med
1 Nat Rev Neurol
4 Neurologia (Engl Ed)
4 Neurology
5 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Ann Neurol

  1. ZUHORN F, Graf T, Klingebiel R, Schabitz WR, et al
    Postvaccinal Encephalitis after ChAdOx1 nCov-19.
    Ann Neurol. 2021;90:506-511.
    PubMed         Abstract available

  2. OSOWICKI J, Morgan H, Harris A, Crawford NW, et al
    Guillain-Barre Syndrome in an Australian state using both mRNA and adenovirus-vector SARS-CoV-2 vaccines.
    Ann Neurol. 2021 Sep 15. doi: 10.1002/ana.26218.


  3. PASCUAL-GONI E, Fehmi J, Lleixa C, Martin-Aguilar L, et al
    Antibodies to the Caspr1/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy.
    Brain. 2021;144:1183-1196.
    PubMed         Abstract available

  4. LUIJTEN LWG, Leonhard SE, van der Eijk AA, Doets AY, et al
    Guillain-Barre syndrome after SARS-CoV-2 infection in an international prospective cohort study.
    Brain. 2021 Sep 23. pii: 6373760. doi: 10.1093.
    PubMed         Abstract available

  5. JENSEN TS, Karlsson P, Gylfadottir SS, Andersen ST, et al
    Painful and non-painful diabetic neuropathy, diagnostic challenges and implications for future management.
    Brain. 2021;144:1632-1645.
    PubMed         Abstract available

  6. BENALLEGUE N, Kebir H, Kapoor R, Crockett A, et al
    The hedgehog pathway suppresses neuropathogenesis in CD4 T cell-driven inflammation.
    Brain. 2021;144:1670-1683.
    PubMed         Abstract available

  7. HAIDER L, Prados F, Chung K, Goodkin O, et al
    Cortical involvement determines impairment 30 years after a clinically isolated syndrome.
    Brain. 2021;144:1384-1395.
    PubMed         Abstract available

  8. COLLORONE S, Prados F, Kanber B, Cawley NM, et al
    Brain microstructural and metabolic alterations detected in vivo at onset of the first demyelinating event.
    Brain. 2021;144:1409-1421.
    PubMed         Abstract available

    Diabet Med

  9. GERA S, Longendyke RL, Minich NM, Malay S, et al
    The COVID-19 Pandemic and Associated Worsening of Diabetic Ketoacidosis Presentation in Youth.
    Diabet Med. 2021 May 30:e14610. doi: 10.1111/dme.14610.
    PubMed         Abstract available


  10. HILLER H, Beachy DE, Lebowitz JJ, Engler S, et al
    Monogenic Diabetes and Integrated Stress Response Genes Display Altered Gene Expression in Type 1 Diabetes.
    Diabetes. 2021 May 25. pii: db21-0070. doi: 10.2337/db21-0070.
    PubMed         Abstract available

  11. GALINDO-ALBARRAN A, Castan S, Santamaria JC, Joffre OP, et al
    The repertoire of newly developing regulatory T cells in the type I diabetes-prone NOD mouse is very diverse.
    Diabetes. 2021 May 25. pii: db20-1072. doi: 10.2337/db20-1072.
    PubMed         Abstract available

  12. JAHOOR F, Hsu JW, Mehta PB, Keene KR, et al
    Metabolomic profiling of patients with A-beta+ Ketosis-Prone Diabetes during diabetic ketoacidosis.
    Diabetes. 2021 May 21. pii: db21-0066. doi: 10.2337/db21-0066.
    PubMed         Abstract available

  13. RODRIGUEZ-CALVO T, Krogvold L, Amirian N, Dahl-Jorgensen K, et al
    One in Ten CD8+ Cells in the Pancreas of Living Individuals With Recent Onset Type 1 Diabetes Recognizes the Preproinsulin Epitope PPI15-24.
    Diabetes. 2021 Jan 7. pii: db20-0908. doi: 10.2337/db20-0908.
    PubMed         Abstract available

  14. OH E, McCown EM, Ahn M, Garcia PA, et al
    Syntaxin 4 enrichment in beta-cells prevents conversion to autoimmune diabetes in non-obese diabetic (NOD) mice.
    Diabetes. 2021 Sep 23. pii: db21-0170. doi: 10.2337/db21-0170.
    PubMed         Abstract available

  15. FORBES JM, McCarthy DA, Kassianos AJ, Baskerville T, et al
    T-Cell Expression and Release of Kidney Injury Molecule-1 in Response to Glucose Variations Initiates Kidney Injury in Early Diabetes.
    Diabetes. 2021 Mar 18. pii: db20-1081. doi: 10.2337/db20-1081.
    PubMed         Abstract available

  16. BRITTEN-JONES AC, Kamel JT, Roberts LJ, Braat S, et al
    Investigating the neuroPRotective effect of Oral Omega-3 Fatty acid Supplementation in type 1 diabetes (nPROOFS1): a randomised, placebo-controlled trial.
    Diabetes. 2021 May 5. pii: db21-0136. doi: 10.2337/db21-0136.
    PubMed         Abstract available

    Int J Clin Pract

  17. GAO R, Kong L, Qing P, Cheng K, et al
    Interleukin-1 beta as Clinically Predictive Risk Marker for Recurrent Pregnancy Loss in Women Positive for Antinuclear Antibody.
    Int J Clin Pract. 2021 Sep 19:e14887. doi: 10.1111/ijcp.14887.
    PubMed         Abstract available

  18. BILGINER MC, Faki S, Ozdemir D, Baser H, et al
    Organ-specific autoimmune markers in adult patients with type 1 diabetes mellitus.
    Int J Clin Pract. 2021 Sep 22:e14842. doi: 10.1111/ijcp.14842.
    PubMed         Abstract available

  19. LEE LE, Pyo JY, Ahn SS, Song JJ, et al
    Clinical significance of large unstained cell count in estimating the current activity of antineutrophil cytoplasmic antibody-associated vasculitis.
    Int J Clin Pract. 2021;75:e14512.
    PubMed         Abstract available

    Intern Med

  20. OKAMOTO S, Tsuboi H, Noma H, Tabuchi D, et al
    Predictive Factors for Pneumomediastinum During Management of Connective Tissue Disease-related Interstitial Lung Disease: A Retrospective Study.
    Intern Med. 2021;60:2887-2897.
    PubMed         Abstract available

  21. MURAKAWA M, Arai S, Kawagoe M, Tomomitsu Y, et al
    A Ruptured Jejunal Arterial Aneurysm in a Young Woman Undergoing Chronic Hemodialysis Due to Myeloperoxidase-antineutrophil Cytoplasmic Antibody-associated Vasculitis.
    Intern Med. 2021;60:2939-2945.
    PubMed         Abstract available

  22. YAMAMOTO K, Oka K, Hasegawa K, Otsuka F, et al
    Sternoclavicular Joint Hypertrophy Involved in Polymyalgia Rheumatica.
    Intern Med. 2021;60:3057.

    J Clin Endocrinol Metab

  23. ESPIARD S, McQueen J, Sherlock M, Ragnarsson O, et al
    Improved Urinary Cortisol Metabolome in Addison Disease: A Prospective Trial of Dual-Release Hydrocortisone.
    J Clin Endocrinol Metab. 2021;106:814-825.
    PubMed         Abstract available

  24. STANTONYONGE N, Sampedro F, Mendez J, Martinez-Horta S, et al
    Structural Grey and White Matter Differences in Patients with Type 1 Diabetes and Impaired Awareness of Hypoglycaemia.
    J Clin Endocrinol Metab. 2020 Nov 12. pii: 5979403. doi: 10.1210.
    PubMed         Abstract available

    J Immunol

  25. MANDEL-BREHM C, Fichtner ML, Jiang R, Winton VJ, et al
    Elevated N-Linked Glycosylation of IgG V Regions in Myasthenia Gravis Disease Subtypes.
    J Immunol. 2021 Sep 20. pii: jimmunol.2100225. doi: 10.4049/jimmunol.2100225.
    PubMed         Abstract available

  26. LI Q, Feng C, Li L, Xu G, et al
    Lipid Receptor G2A-Mediated Signal Pathway Plays a Critical Role in Inflammatory Response by Promoting Classical Macrophage Activation.
    J Immunol. 2021;206:2338-2352.
    PubMed         Abstract available

  27. Top Reads.
    J Immunol. 2021;206:2249.

    J Nephrol

  28. MASSET C, Renaudin K, Kervella D, Chapelet A, et al
    Collapsing glomerulopathy in a patient with APOL1 intermediate-risk genotype triggered by lupus nephritis and SARS-CoV-2 infection: lessons for the clinical nephrologist.
    J Nephrol. 2021 Sep 24. pii: 10.1007/s40620-021-01144.

    J Neuroimmunol

  29. OO WM, Giri P, de Souza A
    AstraZeneca COVID-19 vaccine and Guillain- Barre Syndrome in Tasmania: A causal link?
    J Neuroimmunol. 2021;360:577719.
    PubMed         Abstract available

  30. SRIWASTAVA S, Kataria S, Srivastava S, Kazemlou S, et al
    Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis.
    J Neuroimmunol. 2021;360:577721.
    PubMed         Abstract available

  31. ZELADA-RIOS L, Pacheco-Barrios K, Galecio-Castillo M, Yamunaque-Chunga C, et al
    Acute disseminated encephalomyelitis and COVID-19: A systematic synthesis of worldwide cases.
    J Neuroimmunol. 2021;359:577674.
    PubMed         Abstract available

    J Neurol

  32. AL-ANSARI A, Robertson NP
    Autoimmune encephalitis: clinical presentation, investigation and treatment.
    J Neurol. 2021;268:3935-3937.

  33. PROSPERINI L, Tortorella C, Haggiag S, Ruggieri S, et al
    Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies.
    J Neurol. 2021 Sep 17. pii: 10.1007/s00415-021-10803.
    PubMed         Abstract available

    Kidney Int

  34. ZAVALA-MIRANDA MF, Gonzalez-Ibarra SG, Perez-Arias AA, Uribe-Uribe NO, et al
    New onset systemic lupus erythematosus opening as class V lupus nephritis after COVID-19 vaccination.
    Kidney Int. 2021 Sep 21. pii: S0085-2538(21)00869.

  35. ROVIN BH, Furie R, Teng YKO, Contreras G, et al
    A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.
    Kidney Int. 2021 Sep 21. pii: S0085-2538(21)00862.
    PubMed         Abstract available

    Mult Scler

  36. KASSA RM, Sechi E, Flanagan EP, Kaufmann TJ, et al
    Onset of progressive motor impairment in patients with critical central nervous system demyelinating lesions.
    Mult Scler. 2021;27:895-902.
    PubMed         Abstract available

  37. BIGAUT K, Fabacher T, Kremer L, Ongagna JC, et al
    Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort.
    Mult Scler. 2021;27:729-741.
    PubMed         Abstract available

  38. KUNCHOK A, Lechner-Scott J, Granella F, Trojano M, et al
    Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score.
    Mult Scler. 2021;27:695-705.
    PubMed         Abstract available

  39. LUCIANI L, Ninove L, Zandotti C, Chalvignac V, et al
    Fatal underhanded chronic enterovirus infection associated with anti-CD20 monotherapy for central nervous system demyelinating disease.
    Mult Scler. 2021;27:320-323.
    PubMed         Abstract available

  40. SECHI E, Messina S, Keegan BM, Buciuc M, et al
    Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study.
    Mult Scler. 2021;27:667-673.
    PubMed         Abstract available

  41. REDER AT
    Thoracic flexion provokes circumferential dysesthesia: A symptom of thoracic cord lesions in MS.
    Mult Scler. 2021;27:1008-1013.
    PubMed         Abstract available

  42. DATTA P, Ciplea AI, Rewers-Felkins K, Baker T, et al
    Cladribine transfer into human milk: A case report.
    Mult Scler. 2021;27:799-801.
    PubMed         Abstract available

  43. BUTZKUEVEN H, Trojano M, Kappos L, Spelman T, et al
    Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri((R)) Observational Program (TOP).
    Mult Scler. 2021;27:410-419.
    PubMed         Abstract available

  44. HYUN JW, Kwon YN, Lee HL, Jeong WK, et al
    Recurrence of clinical events at the same anatomical location in patients with MOG antibody-associated disease.
    Mult Scler. 2021;27:449-452.
    PubMed         Abstract available

  45. SALTER A, Stahmann A, Ellenberger D, Fneish F, et al
    Data harmonization for collaborative research among MS registries: A case study in employment.
    Mult Scler. 2021;27:281-289.
    PubMed         Abstract available

  46. LIBERTINOVA J, Meluzinova E, Nema E, Rockova P, et al
    Elevated D-dimer as an immediate response to alemtuzumab treatment.
    Mult Scler. 2021;27:151-154.
    PubMed         Abstract available

  47. ZHANG J, Giorgio A, Vinciguerra C, Stromillo ML, et al
    Gray matter atrophy cannot be fully explained by white matter damage in patients with MS.
    Mult Scler. 2021;27:39-51.
    PubMed         Abstract available

  48. GEORGE IC, El Mendili MM, Inglese M, Azevedo CJ, et al
    Cerebellar volume loss in radiologically isolated syndrome.
    Mult Scler. 2021;27:130-133.
    PubMed         Abstract available

  49. CACCIAGUERRA L, Rocca MA, Storelli L, Radaelli M, et al
    Mapping white matter damage distribution in neuromyelitis optica spectrum disorders with a multimodal MRI approach.
    Mult Scler. 2021;27:841-854.
    PubMed         Abstract available

  50. CAI MT, Zheng Y, Shen CH, Yang F, et al
    Evaluation of brain and spinal cord lesion distribution criteria at disease onset in distinguishing NMOSD from MS and MOG antibody-associated disorder.
    Mult Scler. 2021;27:871-882.
    PubMed         Abstract available

  51. LONGBRAKE EE, Mao-Draayer Y, Cascione M, Zielinski T, et al
    Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity.
    Mult Scler. 2021;27:883-894.
    PubMed         Abstract available

  52. MORROW SA, Conway D, Fuchs T, Wojcik C, et al
    Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapses.
    Mult Scler. 2021;27:1077-1087.
    PubMed         Abstract available

    MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - Yes.
    Mult Scler. 2021;27:1002-1004.

  54. CROSS AH, Naismith RT
    MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - No.
    Mult Scler. 2021;27:1004-1005.

  55. ZACKOWSKI KM, Freeman J, Brichetto G, Centonze D, et al
    Prioritizing progressive MS rehabilitation research: A call from the International Progressive MS Alliance.
    Mult Scler. 2021;27:989-1001.
    PubMed         Abstract available

    Spinal cord and brain MRI should be routinely performed during follow-up in patients with NMOSD - Yes.
    Mult Scler. 2021;27:13-15.

  57. JURYNCZYK M, Messina S, Palace J
    Spinal cord and brain MRI should be routinely performed during follow-up in patients with NMOSD - No.
    Mult Scler. 2021;27:15-16.

  58. NAYAK S, Sechi E, Flanagan EP, Messina S, et al
    Inflammatory activity following motor progression due to critical CNS demyelinating lesions.
    Mult Scler. 2021;27:1037-1045.
    PubMed         Abstract available

  59. MANCINELLI CR, Scarpazza C, Cordioli C, De Rossi N, et al
    Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.
    Mult Scler. 2021;27:790-794.
    PubMed         Abstract available

    N Engl J Med

  60. BRADBURY CA, Pell J, Hill Q, Bagot C, et al
    Mycophenolate Mofetil for First-Line Treatment of Immune Thrombocytopenia.
    N Engl J Med. 2021;385:885-895.
    PubMed         Abstract available

    Nat Rev Neurol

  61. BODINI B, Tonietto M, Airas L, Stankoff B, et al
    Positron emission tomography in multiple sclerosis - straight to the target.
    Nat Rev Neurol. 2021 Sep 20. pii: 10.1038/s41582-021-00537.
    PubMed         Abstract available

    Neurologia (Engl Ed)

  62. PERAL QUIROS A, Acebron F, Del Carmen Blanco Valero M, Labella Alvarez F, et al
    Recurrent Miller Fisher syndrome: Case report.
    Neurologia (Engl Ed). 2021;36:561-562.

  63. JAUREGUI-LARRANAGA C, Ostolaza-Ibanez A, Martin-Bujanda M
    Acute transverse myelitis following SARS-CoV-2 infection.
    Neurologia (Engl Ed). 2021;36:572-574.

  64. CASTILLO-ALVAREZ F, Perez-Matute P, Oteo JA, Marzo-Sola ME, et al
    The influence of interferon beta-1b on gut microbiota composition in patients with multiple sclerosis.
    Neurologia (Engl Ed). 2021;36:495-503.
    PubMed         Abstract available

  65. ARAGONES JM, Altimiras J, Alonso F, Celedon G, et al
    Incidence and clinical characteristics of Guillain-Barre syndrome in Osona (Barcelona, Spain), 2003-2016.
    Neurologia (Engl Ed). 2021;36:525-530.
    PubMed         Abstract available


  66. MARRIE RA, Maxwell C, Mahar A, Ekuma O, et al
    Colorectal Cancer Survival in Multiple Sclerosis: A Matched Cohort Study.
    Neurology. 2021 Sep 15. pii: WNL.0000000000012634.
    PubMed         Abstract available

  67. RICE J, Xiang XM
    Comparing the Effectiveness of Therapies in People With Secondary Progressive Multiple Sclerosis.
    Neurology. 2021;97:e972-e974.

  68. MERLO D, Stankovich J, Bai C, Kalincik T, et al
    Association Between Cognitive Trajectories and Disability Progression in Patients With Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2021 Sep 23. pii: WNL.0000000000012850.
    PubMed         Abstract available

  69. RADCLIFFE C, Potnis K, Peng TJ, DeCroce-Movson E, et al
    Teaching NeuroImage: Papilledema and Pachymeningitis: An Atypical Presentation of Granulomatosis With Polyangiitis.
    Neurology. 2021;97:e1060-e1061.

    PLoS One

  70. KIM SE, Kim J, Lee JY, Lee SB, et al
    Octreotide inhibits secretion of IGF-1 from orbital fibroblasts in patients with thyroid-associated ophthalmopathy via inhibition of the NF-kappaB pathway.
    PLoS One. 2021;16:e0249988.
    PubMed         Abstract available

  71. DIRNENA-FUSINI I, Am MK, Fougner AL, Carlsen SM, et al
    Physiological effects of intraperitoneal versus subcutaneous insulin infusion in patients with diabetes mellitus type 1: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0249611.
    PubMed         Abstract available

  72. MOHD R, Mohammad Kazmin NE, Abdul Cader R, Abd Shukor N, et al
    Long term outcome of immunoglobulin A (IgA) nephropathy: A single center experience.
    PLoS One. 2021;16:e0249592.
    PubMed         Abstract available

  73. PRIDHAM G, Hossain S, Rawji KS, Zhang Y, et al
    A metric learning method for estimating myelin content based on T2-weighted MRI from a de- and re-myelination model of multiple sclerosis.
    PLoS One. 2021;16:e0249460.
    PubMed         Abstract available

  74. ROLDAN CA, Sibbitt WL Jr, Greene ER, Qualls CR, et al
    Libman-Sacks endocarditis and associated cerebrovascular disease: The role of medical therapy.
    PLoS One. 2021;16:e0247052.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.